FDA mandates new vision loss warning for all GLP-1 weight loss and diabetes drugs
The US Food and Drug Administration has required all manufacturers of GLP-1 medications to add a safety warning regarding a rare eye condition that can cause sudden vision loss.
By LAS News Desk · Published 10 Nov 2026, 12:46 WAT

The United States Food and Drug Administration (FDA) has mandated that all manufacturers of glucagon-like peptide-1 (GLP-1) receptor agonists include a new safety warning on their drug labels. This regulatory action, announced on Monday, addresses a potential increased risk of nonarteritic anterior ischemic optic neuropathy, commonly abbreviated as NAION. The condition is characterized by a sudden decrease in vision, which in severe cases can result in permanent blindness. The FDA stated that this warning must be added to the labeling of every currently marketed GLP-1 product, a class of medications widely used for the treatment of obesity, type 2 diabetes, and other medical conditions.
The decision follows a comprehensive review by FDA scientists of clinical trial data, real-world patient records, and published medical studies. The agency identified that cases of NAION have been reported for all GLP-1 drugs currently available on the market. While the FDA noted that a definitive causal relationship between the use of these medications and the development of NAION has not been established, the available evidence suggests a potential association. The warning is intended to ensure that both patients and healthcare providers are informed of this rare but serious risk.
Background
Popularity for drugs like Novo Nordisk’s Ozempic and Wegovy, alongside Eli Lilly’s Mounjaro and Zepbound, has risen sharply because of their success in managing weight and treating diabetes. The class includes approximately a dozen injectable or pill-based drugs. The FDA’s inquiry into the ocular issue was partly triggered by a 2024 medical study that associated NAION with users of semaglutide, the key component in Ozempic and Wegovy.
Dr. Neuro-ophthalmologist Joseph Rizzo, a co-author of the 2024 research, explained that his group and the FDA have worked together for a while to collect and examine relevant data. Although he did not anticipate the timing of the agency’s decision, he expressed that he was not surprised by the addition of the warning. Dr. Rizzo emphasized that while the evidence indicates an increased risk, he does not discourage patients from using these medications, noting that they have provided profound benefits to a large number of individuals.
An analysis of 126 clinical trials involving more than 134,000 patients revealed that the incidence of NAION was 6.4 cases per 100,000 patient-years among those using GLP-1 drugs. In comparison, the rate was 3.Patients on alternative therapies or placebos experienced an incidence rate of 8 cases per 100,000 patient-years. Additional observational research has likewise detected higher risks, which reinforces the FDA’s worries. NAION results from diminished circulation to the anterior section of the optic nerve, although the precise biological processes remain unclear. The condition can affect individuals not taking GLP-1 drugs, with an estimated prevalence of 2 to 10 cases per 100,000 adults over the age of 50.
Why it matters
This regulatory move impacts millions of patients currently using or considering GLP-1 therapies for weight loss and diabetes management. The addition of the warning label aims to improve transparency regarding the potential risks associated with these blockbuster medications. Novo Nordisk reacted to the FDA’s ruling by asserting that the available evidence does not prove a causal link. The firm expressed confidence in the benefit-risk profile of its GLP-1 medicines. Eli Lilly, the manufacturer of Mounjaro, Zepbound, and Foundayo, was contacted for comment but had not responded at the time of reporting.
The condition, sometimes referred to as an "eye stroke," currently has no proven treatments, making prevention and early awareness critical. By requiring the warning, the FDA is ensuring that the potential for sudden vision loss is clearly communicated in the drug labeling. This allows healthcare providers to counsel patients on the signs and symptoms of NAION and to monitor for any changes in vision during treatment. The decision highlights the ongoing scrutiny of widely used medications as new safety data emerges from both clinical settings and real-world usage.
What happens next
Manufacturers of all GLP-1 drugs are now required to update their product labels to include the new safety warning. The FDA’s decision is based on the current body of evidence, including the analysis of 126 trials and observational studies. While the agency has not established a definitive causal link, the requirement for the warning reflects a precautionary approach to patient safety. Patients and doctors will now have access to this information in the official drug labeling, which may influence prescribing practices and patient discussions regarding the risks and benefits of these therapies.
Sources
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound — CNBC
- FDA warns of rare vision-loss side effect from GLP-1 drugs — CBS News
- GLP-1s must now include warning for potential increased risk of vision loss, FDA announces — CBS News
- FDA orders blindness risk warning on weight loss drugs — Sky News
- STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition — STAT News
Spotted an error? · Corrections policy
Related stories

Prediction markets Polymarket and Kalshi launch wagers on US measles and vaccine outcomes
Online prediction platforms are now allowing users to bet on US public health events, including measles case numbers and FDA vaccine approvals, prompting experts to warn about the risks of unregulated gambling in the health sector.
LAS News Desk · 15 Nov 2026, 07:48 WAT · 1 source

FDA shelves Trump‑era fast‑track drug review programme
The FDA has quietly dropped the National Priority Voucher program launched in June 2025, after no new vouchers were issued since former Commissioner Marty Makary left in May. The move follows criticism of the programme’s political oversight and lack of progress.
LAS News Desk · 12 Nov 2026, 20:16 WAT · 2 sources

NAFDAC destroys counterfeit and expired products valued at N100 billion in Ogun State
The National Agency for Food and Drug Administration and Control demolished fake, expired and banned drugs, cosmetics, alcoholic drinks and other unwholesome items worth about N100 billion at a dump site in Ogere Remo, Ogun State, and said suspects will be prosecuted.
LAS News Desk · 21 Nov 2026, 00:45 WAT · 2 sources

Trump says Taiwan will secure 30% of Alaska LNG output for 20 years
US President Donald Trump stated that Taiwan has committed to purchasing 30% of gas from the proposed Alaska LNG project over two decades, a move he says guarantees the project's success.
Photo: Ali Shaker/VOA / Wikimedia Commons · Public domain
LAS News Desk · 10 Nov 2026, 01:39 WAT · 2 sources

GSK shares fall on vaccine weakness and restructuring costs despite profit beat
GSK shares dropped 5.5% after reporting a 19% fall in pre-tax profit to £1.9bn, driven by weaker vaccine sales and £318m in restructuring charges, despite beating revenue expectations.
LAS News Desk · 28 Oct 2026, 14:45 WAT · 1 source

IMF lifts UK 2026 growth outlook to 1.3% as it warns of global economic strain
The IMF has upgraded its 2026 UK growth outlook to 1.3% but warned that depleting oil stocks and high debt levels could soon test the global economy's stability.
LAS News Desk · 11 Nov 2026, 08:05 WAT · 2 sources
More Business news ›
- Alex Spiro and Tom Brady consider minority stakes in Chelsea as Clearlake seeks new investors
- Jensen Huang to give first public Senate testimony on spy allegations
- Anthropic's US IPO values firm at $1.5tn as founders set to become multi‑billionaires
- UK energy price cap set to rise 26% in January, adding £443 to average household bills
- Nvidia creates board‑level National Security and Export Control Oversight Committee after CEO resignation